{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:46:52Z","timestamp":1792003612121,"version":"4.4.0"},"reference-count":102,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008240","name":"FRQSC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008240","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Fonds de Recherche du Qu\u00e9bec - Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["RN408399"],"award-info":[{"award-number":["RN408399"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["430975"],"award-info":[{"award-number":["430975"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["RN408399 \\u2013 430975"],"award-info":[{"award-number":["RN408399 \\u2013 430975"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.phrs.2022.106157","type":"journal-article","created":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T20:03:55Z","timestamp":1646424235000},"page":"106157","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Targeting the residual cardiovascular risk by specific anti-inflammatory interventions as a therapeutic strategy in atherosclerosis"],"prefix":"10.1016","volume":"178","author":[{"given":"Anouar","family":"Hafiane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella S.","family":"Daskalopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2022.106157_bib1","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1161\/CIR.0000000000000950","article-title":"Heart disease and stroke statistics-2021 update: a report from the american heart association","volume":"143","author":"Virani","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2022.106157_bib2","article-title":"Vulnerable plaque, characteristics, detection, and potential therapies","volume":"6","author":"Hafiane","year":"2019","journal-title":"J. Cardiovasc. Dev. Dis."},{"key":"10.1016\/j.phrs.2022.106157_bib3","article-title":"Nlrp3 inflammasome: a potential alternative therapy target for atherosclerosis","volume":"2020","author":"Liu","year":"2020","journal-title":"Evid. -Based Complement. Altern. Med."},{"key":"10.1016\/j.phrs.2022.106157_bib4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis \u2014 an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.phrs.2022.106157_bib5","first-page":"828","article-title":"The selective nlrp3-inflammasome inhibitor mcc950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction","volume":"38","author":"van Hout","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2022.106157_bib6","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2022.106157_bib7","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.012219","article-title":"Novel insights into the nlrp3 inflammasome in atherosclerosis","volume":"8","author":"Jin","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.phrs.2022.106157_bib8","doi-asserted-by":"crossref","first-page":"3937","DOI":"10.1093\/eurheartj\/ehz283","article-title":"Immunotherapy for cardiovascular disease","volume":"40","author":"Lutgens","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2022.106157_bib9","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCRESAHA.118.313129","article-title":"Anticytokine agents: Targeting interleukin signaling pathways for the treatment of atherothrombosis","volume":"124","author":"Ridker","year":"2019","journal-title":"Circ. Res."},{"key":"10.1016\/j.phrs.2022.106157_bib10","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3389\/fcvm.2019.00016","article-title":"Targeting residual inflammatory risk: a shifting paradigm for atherosclerotic disease","volume":"6","author":"Aday","year":"2019","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.phrs.2022.106157_bib11","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(09)61717-7","article-title":"C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis","volume":"375","author":"Kaptoge","year":"2010","journal-title":"Lancet (Lond., Engl. )"},{"key":"10.1016\/j.phrs.2022.106157_bib12","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated c-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.phrs.2022.106157_bib13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","article-title":"Relationship of c-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the cantos randomised controlled trial","volume":"391","author":"Ridker","year":"2018","journal-title":"Lancet (Lond., Engl. )"},{"key":"10.1016\/j.phrs.2022.106157_bib14","doi-asserted-by":"crossref","first-page":"147","DOI":"10.21037\/atm.2019.02.34","article-title":"Anti-inflammatory therapy for cardiovascular disease","volume":"7","author":"Kosmas","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.phrs.2022.106157_bib15","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/cvr\/cvz166","article-title":"Immunometabolism and atherosclerosis: perspectives and clinical significance: A position paper from the working group on atherosclerosis and vascular biology of the european society of cardiology","volume":"115","author":"Ketelhuth","year":"2019","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.phrs.2022.106157_bib16","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1161\/STROKEAHA.119.026280","article-title":"Intensive statin therapy compromises the adiponectin-adipor pathway in the human monocyte-macrophage lineage","volume":"50","author":"Gasbarrino","year":"2019","journal-title":"Stroke"},{"key":"10.1016\/j.phrs.2022.106157_bib17","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.tibs.2016.09.002","article-title":"Mechanism and regulation of nlrp3 inflammasome activation","volume":"41","author":"He","year":"2016","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.phrs.2022.106157_bib18","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1161\/01.ATV.0000064374.15232.C3","article-title":"Lack of interleukin-1beta decreases the severity of atherosclerosis in apoe-deficient mice","volume":"23","author":"Kirii","year":"2003","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.phrs.2022.106157_bib19","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.atherosclerosis.2011.02.026","article-title":"Monoclonal antibodies targeting il-1 beta reduce biomarkers of atherosclerosis in vitro and inhibit atherosclerotic plaque formation in apolipoprotein e-deficient mice","volume":"216","author":"Bhaskar","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2022.106157_bib20","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1038\/ni.2704","article-title":"Fatty acid-induced mitochondrial uncoupling elicits inflammasome-independent il-1\u03b1 and sterile vascular inflammation in atherosclerosis","volume":"14","author":"Freigang","year":"2013","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.phrs.2022.106157_bib21","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nm.3893","article-title":"Inflammasomes: mechanism of action, role in disease, and therapeutics","volume":"21","author":"Guo","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2022.106157_bib22","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1016\/j.jacc.2017.09.028","article-title":"Interleukin-1 beta as a target for atherosclerosis therapy: biological basis of cantos and beyond","volume":"70","author":"Libby","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2022.106157_bib23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1146\/annurev-immunol-032414-112306","article-title":"Inflammasome-independent regulation of il-1-family cytokines","volume":"33","author":"Netea","year":"2015","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.phrs.2022.106157_bib24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.gene.2004.05.002","article-title":"Structural, expression, and evolutionary analysis of mouse cias1","volume":"338","author":"Anderson","year":"2004","journal-title":"Gene"},{"key":"10.1016\/j.phrs.2022.106157_bib25","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.tibs.2016.09.002","article-title":"Mechanism and regulation of nlrp3 inflammasome activation","volume":"41","author":"He","year":"2016","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.phrs.2022.106157_bib26","doi-asserted-by":"crossref","first-page":"19487","DOI":"10.1074\/jbc.M116.741082","article-title":"Asc pyrin domain self-associates and binds nlrp3 protein using equivalent binding interfaces","volume":"291","author":"Oroz","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2022.106157_bib27","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s13238-013-2113-2","article-title":"Cellular localization of nlrp3 inflammasome","volume":"4","author":"Wang","year":"2013","journal-title":"Protein Cell"},{"key":"10.1016\/j.phrs.2022.106157_bib28","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.cell.2010.01.040","article-title":"The inflammasomes","volume":"140","author":"Schroder","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2022.106157_bib29","doi-asserted-by":"crossref","DOI":"10.1289\/EHP8314","article-title":"Assessing the association of mitochondrial function and inflammasome activation in murine macrophages exposed to select mitotoxic tri-organotin compounds","volume":"129","author":"Childers","year":"2021","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.phrs.2022.106157_bib30","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.18557.1","article-title":"Right place, right time: localisation and assembly of the nlrp3 inflammasome","volume":"8","author":"Hamilton","year":"2019","journal-title":"F1000Research."},{"key":"10.1016\/j.phrs.2022.106157_bib31","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1038\/ni.3202","article-title":"The receptor nlrp3 is a transcriptional regulator of th2 differentiation","volume":"16","author":"Bruchard","year":"2015","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.phrs.2022.106157_bib32","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.atherosclerosis.2017.10.027","article-title":"Nlrp3 inflammasome pathways in atherosclerosis","volume":"267","author":"Baldrighi","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2022.106157_bib33","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41586-018-0761-3","article-title":"Ptdins4p on dispersed trans-golgi network mediates nlrp3 inflammasome activation","volume":"564","author":"Chen","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2022.106157_bib34","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1016\/j.jacc.2017.09.028","article-title":"Interleukin-1 beta as a target for atherosclerosis therapy: biological basis of cantos and beyond","volume":"70","author":"Libby","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2022.106157_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011765","article-title":"Cholesterol crystals activate the nlrp3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation","volume":"5","author":"Rajam\u00e4ki","year":"2010","journal-title":"PloS One"},{"key":"10.1016\/j.phrs.2022.106157_bib36","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1161\/CIRCULATIONAHA.117.032636","article-title":"Cholesterol efflux pathways suppress inflammasome activation, netosis, and atherogenesis","volume":"138","author":"Westerterp","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2022.106157_bib37","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1016\/j.ijcard.2013.01.211","article-title":"Nalp3 inflammasome is activated and required for vascular smooth muscle cell calcification","volume":"168","author":"Wen","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.phrs.2022.106157_bib38","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1161\/CIRCULATIONAHA.113.002714","article-title":"Sterol regulatory element binding protein 2 activation of nlrp3 inflammasome in endothelium mediates hemodynamic-induced atherosclerosis susceptibility","volume":"128","author":"Xiao","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2022.106157_bib39","first-page":"352","article-title":"T helper 1 immunity requires complement-driven nlrp3 inflammasome activity in cd4+ t cells","author":"Arbore","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.phrs.2022.106157_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01592","article-title":"Regulatory mechanisms of the nlrp3 inflammasome, a novel immune-inflammatory marker in cardiovascular diseases","volume":"10","author":"An","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2022.106157_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2011.18","article-title":"Atherosclerosis in apoe-deficient mice progresses independently of the nlrp3 inflammasome","volume":"2","author":"Menu","year":"2011","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.phrs.2022.106157_bib42","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.atherosclerosis.2006.11.026","article-title":"Differential role and tissue specificity of interleukin-1\u03b1 gene expression in atherogenesis and lipid metabolism","volume":"195","author":"Kamari","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.phrs.2022.106157_bib43","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bbrc.2011.01.008","article-title":"Reduced atherosclerosis and inflammatory cytokines in apolipoprotein-e-deficient mice lacking bone marrow-derived interleukin-1\u03b1","volume":"405","author":"Kamari","year":"2011","journal-title":"Biochem Biophys. Res Commun."},{"key":"10.1016\/j.phrs.2022.106157_bib44","doi-asserted-by":"crossref","first-page":"12162","DOI":"10.1016\/S0021-9258(18)98874-5","article-title":"Involvement of a calpain-like protease in the processing of the murine interleukin 1 alpha precursor","volume":"266","author":"Carruth","year":"1991","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2022.106157_bib45","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/4293206","article-title":"Nlrp3 inflammasome and its central role in the cardiovascular diseases","volume":"2020","author":"Tong","year":"2020","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.phrs.2022.106157_bib46","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1161\/CIRCULATIONAHA.114.013730","article-title":"Anti-inflammatory and antiatherogenic effects of the nlrp3 inflammasome inhibitor arglabin in apoe2.Ki mice fed a high-fat diet","volume":"131","author":"Abderrazak","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2022.106157_bib47","first-page":"30","article-title":"Long-term results of combination therapy for locally advanced breast cancer","author":"Zhumakayeva","year":"2018","journal-title":"Georgian Med. News"},{"key":"10.1016\/j.phrs.2022.106157_bib48","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1186\/s12974-020-01933-y","article-title":"Mcc950, a selective nlpr3 inflammasome inhibitor, improves neurologic function and survival after cardiac arrest and resuscitation","volume":"17","author":"Jiang","year":"2020","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.phrs.2022.106157_bib49","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nm.3806","article-title":"A small-molecule inhibitor of the nlrp3 inflammasome for the treatment of inflammatory diseases","volume":"21","author":"Coll","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2022.106157_bib50","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41589-019-0277-7","article-title":"Mcc950 directly targets the nlrp3 atp-hydrolysis motif for inflammasome inhibition","volume":"15","author":"Coll","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.phrs.2022.106157_bib51","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41589-019-0277-7","article-title":"Mcc950 directly targets the nlrp3 atp-hydrolysis motif for inflammasome inhibition","volume":"15","author":"Coll","year":"2019","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.phrs.2022.106157_bib52","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.bbrc.2017.11.025","article-title":"Inhibition of the nlrp3 inflammasome attenuates foam cell formation of thp-1 macrophages by suppressing ox-ldl uptake and promoting cholesterol efflux","volume":"495","author":"Chen","year":"2018","journal-title":"Biochem Biophys. Res Commun."},{"key":"10.1016\/j.phrs.2022.106157_bib53","doi-asserted-by":"crossref","first-page":"99740","DOI":"10.18632\/oncotarget.20763","article-title":"Nlrp3-inflammasome inhibition prevents high fat and high sugar diets-induced heart damage through autophagy induction","volume":"8","author":"Pavillard","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2022.106157_bib54","doi-asserted-by":"crossref","first-page":"11128","DOI":"10.1038\/s41598-019-47610-w","article-title":"Miltefosine increases macrophage cholesterol release and inhibits nlrp3-inflammasome assembly and il-1\u03b2 release","volume":"9","author":"Iacano","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2022.106157_bib55","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/jac\/dks275","article-title":"Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis","volume":"67","author":"Dorlo","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.phrs.2022.106157_bib56","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/00001813-200011000-00006","article-title":"Phase ii study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients","volume":"11","author":"Smorenburg","year":"2000","journal-title":"Anti Cancer Drugs"},{"key":"10.1016\/j.phrs.2022.106157_bib57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0163667","article-title":"Miltefosine suppresses hepatic steatosis by activating ampk signal pathway","volume":"11","author":"Fang","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.phrs.2022.106157_bib58","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.bbamem.2016.03.004","article-title":"Hemolytic potential of miltefosine is dependent on cell concentration: Implications for in vitro cell cytotoxicity assays and pharmacokinetic data","volume":"1858","author":"Alonso","year":"2016","journal-title":"Biochim. Et. Biophys. Acta"},{"key":"10.1016\/j.phrs.2022.106157_bib59","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2022.106157_bib60","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.phrs.2022.106157_bib61","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.berh.2019.01.012","article-title":"Toll-like receptor 2 is overexpressed in familial mediterranean fever patients and is inhibited by colchicine treatment","volume":"32","author":"Ben-David","year":"2018","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"10.1016\/j.phrs.2022.106157_bib62","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s10620-019-05729-w","article-title":"Acute colchicine poisoning causes endotoxemia via the destruction of intestinal barrier function: The curative effect of endotoxin prevention in a murine model","volume":"65","author":"Horioka","year":"2020","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.phrs.2022.106157_bib63","unstructured":"Colchicine cardiovascular outcomes trial (colcot). \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02551094\u3009. (Assessed 2 January 2021)."},{"key":"10.1016\/j.phrs.2022.106157_bib64","unstructured":"Lodoco2 trial: A randomised controlled trial on the effect of low dose colchicine for secondary prevention of cardiovascular disease in patients with established, stable coronary artery disease. \u3008http:\/\/www.anzctr.org.au\/TrialSearch.aspx?searchTxt=LoDoCo2&isBasic=True\u3009. Assessed 2 January 2021."},{"key":"10.1016\/j.phrs.2022.106157_bib65","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1161\/CIRCULATIONAHA.119.045256","article-title":"From cantos to cirt to colcot to clinic","volume":"141","author":"Ridker","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2022.106157_bib66","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1161\/CIRCULATIONAHA.120.050771","article-title":"Colchicine in patients with acute coronary syndrome: the australian cops randomized clinical trial","volume":"142","author":"Tong","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2022.106157_bib67","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1093\/eurheartj\/ehaa659","article-title":"Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the colchicine cardiovascular outcomes trial (colcot)","volume":"41","author":"Bouabdallaoui","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2022.106157_bib68","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1093\/eurjpc\/zwab045","article-title":"Efficacy and safety of colchicine for the prevention of major cardiovascular and cerebrovascular events in patients with coronary artery disease: a systematic review and meta-analysis on 12 869 patients","volume":"28","author":"Andreis","year":"2022","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.phrs.2022.106157_bib69","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1093\/eurheartj\/ehab115","article-title":"Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials","volume":"42","author":"Fiolet","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2022.106157_bib70","article-title":"Efficacy and safety of colchicine in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials","author":"Byty\u00e7i","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2022.106157_bib71","first-page":"776","article-title":"Colchicine for secondary prevention of cardiovascular disease: a systematic review and meta-analysis of randomized controlled trials","volume":"37","author":"Samuel","year":"2021","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.phrs.2022.106157_bib72","unstructured":"Study to investigate the benefits of colchicine in patients with covid-19. 2020. \u3008https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04603690\u3009."},{"key":"10.1016\/j.phrs.2022.106157_bib73","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/ard.2008.092668","article-title":"Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature","volume":"68","author":"Visser","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2022.106157_bib74","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.amjcard.2011.06.054","article-title":"Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease","volume":"108","author":"Micha","year":"2011","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.phrs.2022.106157_bib75","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2019","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.phrs.2022.106157_bib76","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2022.106157_bib77","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1080\/19420862.2015.1081323","article-title":"The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing il-1\u03b2","volume":"7","author":"Rondeau","year":"2015","journal-title":"mAbs"},{"key":"10.1016\/j.phrs.2022.106157_bib78","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1161\/CIRCULATIONAHA.112.122556","article-title":"Effects of interleukin-1\u03b2 inhibition with canakinumab on hemoglobin a1c, lipids, c-reactive protein, interleukin-6, and fibrinogen: a phase iib randomized, placebo-controlled trial","volume":"126","author":"Ridker","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2022.106157_bib79","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1093\/eurheartj\/ehy310","article-title":"Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: Analyses from the canakinumab anti-inflammatory thrombosis outcomes study (cantos)","volume":"39","author":"Ridker","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2022.106157_bib80","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/S0140-6736(17)32247-X","article-title":"Effect of interleukin-1\u03b2 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Ridker","year":"2017","journal-title":"Lancet (Lond., Engl. )"},{"key":"10.1016\/j.phrs.2022.106157_bib81","doi-asserted-by":"crossref","first-page":"695","DOI":"10.21037\/jtd.2018.01.119","article-title":"Anti-inflammatory therapy with canakinumab for atherosclerotic disease: Lessons from the cantos trial","volume":"10","author":"Thompson","year":"2018","journal-title":"J. Thorac. Dis."},{"key":"10.1016\/j.phrs.2022.106157_bib82","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/eurheartj\/ehu272","article-title":"The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-st elevation acute coronary syndromes: the mrc-ila heart study","volume":"36","author":"Morton","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2022.106157_bib83","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155944","article-title":"Effect of the il-1 receptor antagonist kineret\u00ae on disease phenotype in mdx mice","volume":"11","author":"Benny Klimek","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2022.106157_bib84","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1093\/eurheartj\/ehy128","article-title":"Interleukin-1 blockade in cardiovascular diseaSes: A Clinical update","volume":"39","author":"Buckley","year":"2018","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.phrs.2022.106157_bib85","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.119.014941","article-title":"Interleukin-1 blockade inhibits the acute inflammatory response in patients with st-segment-elevation myocardial infarction","volume":"9","author":"Abbate","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.phrs.2022.106157_bib86","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1056\/NEJMoa2027892","article-title":"Phase 3 trial of interleukin-1 trap rilonacept in recurrent pericarditis","volume":"384","author":"Klein","year":"2020","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.phrs.2022.106157_bib87","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1161\/CIRCRESAHA.121.319077","article-title":"Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular disease","volume":"128","author":"Ridker","year":"2021","journal-title":"Circ. Res."},{"key":"10.1016\/j.phrs.2022.106157_bib88","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.bbi.2017.11.020","article-title":"Association between a functional interleukin 6 receptor genetic variant and risk of depression and psychosis in a population-based birth cohort","volume":"69","author":"Khandaker","year":"2018","journal-title":"Brain Behav., Immun."},{"key":"10.1016\/j.phrs.2022.106157_bib89","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.jacc.2021.02.049","article-title":"Randomized trial of interleukin-6 receptor inhibition in patients with acute st-segment elevation myocardial infarction","volume":"77","author":"Broch","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2022.106157_bib90","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"Il-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (rescue): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet (Lond., Engl. )"},{"key":"10.1016\/j.phrs.2022.106157_bib91","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/CRD.0000000000000021","article-title":"Inflammation and atherosclerosis: a review of the role of interleukin-6 in the development of atherosclerosis and the potential for targeted drug therapy","volume":"22","author":"Hartman","year":"2014","journal-title":"Cardiol. Rev."},{"key":"10.1016\/j.phrs.2022.106157_bib92","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1016\/j.jacc.2021.02.060","article-title":"Inhibiting interleukin-6 to reduce cardiovascular event rates","volume":"77","author":"Ridker","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2022.106157_bib93","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/annrheumdis-2013-204345","article-title":"Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: Measure, a randomised, placebo-controlled study","volume":"74","author":"McInnes","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2022.106157_bib94","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.biopha.2016.04.043","article-title":"Atorvastatin suppresses nlrp3 inflammasome activation via tlr4\/myd88\/nf-\u03bab signaling in pma-stimulated thp-1 monocytes","volume":"82","author":"Kong","year":"2016","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.phrs.2022.106157_bib95","doi-asserted-by":"crossref","unstructured":"K. Koushki , S.K. Shahbaz, K. Mashayekhi , M. Sadeghi , Z.D. Zayeri ,\u00a0M.Y.\u00a0Taba , M. Banach , K. Al-Rasadi , T.P.\u00a0Johnston, A. Sahebkar , Anti-inflammatory action of statins in cardiovascular disease: The role of inflammasome and toll-like receptor pathways. Clinical Reviews in Allergy & Immunology. 2020.","DOI":"10.1007\/s12016-020-08791-9"},{"key":"10.1016\/j.phrs.2022.106157_bib96","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1194\/jlr.S091280","article-title":"Inflammasomes, neutrophil extracellular traps, and cholesterol","volume":"60","author":"Tall","year":"2019","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.phrs.2022.106157_bib97","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.7150\/thno.45939","article-title":"Nlrp3 inflammasome via il-1\u03b2 regulates pcsk9 secretion","volume":"10","author":"Ding","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.phrs.2022.106157_bib98","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s00392-016-0991-z","article-title":"Atorvastatin treatment and ldl cholesterol target attainment in patients at very high cardiovascular risk","volume":"105","author":"Laufs","year":"2016","journal-title":"Clin. Res. Cardiol.: Off. J. Ger. Card. Soc."},{"key":"10.1016\/j.phrs.2022.106157_bib99","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease","volume":"61","author":"Nidorf","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.phrs.2022.106157_bib100","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1161\/CIRCULATIONAHA.120.050771","article-title":"Colchicine in patients with acute coronary syndrome","volume":"142","author":"Tong","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2022.106157_bib101","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12967-021-02727-3","article-title":"Rosuvastatin exerts anti-atherosclerotic effects by improving macrophage-related foam cell formation and polarization conversion via mediating autophagic activities","volume":"19","author":"Zhang","year":"2021","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.phrs.2022.106157_bib102","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1161\/CIRCULATIONAHA.116.025158","article-title":"Effect of rosuvastatin on carotid intima-media thickness in children with heterozygous familial hypercholesterolemia: the charon study (hypercholesterolemia in children and adolescents taking rosuvastatin open label)","volume":"136","author":"Braamskamp","year":"2017","journal-title":"Circulation"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822001025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822001025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T03:22:37Z","timestamp":1777605757000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661822001025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":102,"alternative-id":["S1043661822001025"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106157","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the residual cardiovascular risk by specific anti-inflammatory interventions as a therapeutic strategy in atherosclerosis","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106157","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106157"}}